Phase II study of volociximab (M200), an a5fl1 anti-integrin antibody in refractory metastatic clear cell renal cell cancer (RCC)

Authors
Category Primary study
JournalJournal Clinical Oncology
Year 2006
This article has no abstract
Epistemonikos ID: 35cf7db837e517e9719a50eaef612ae956cf0a2c
First added on: Jun 25, 2020